

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

[AbbVie](#)

RRID:SCR_010484

Type: Tool

Proper Citation

AbbVie (RRID:SCR_010484)

Resource Information

URL: <http://www.abbvie.com/>

Proper Citation: AbbVie (RRID:SCR_010484)

Description: A research-based biopharmaceutical company that develops advanced therapies to address global health problems.

Abbreviations: ABBV

Synonyms: AbbVie Inc., AbbVie Deutschland GmbH & Co KG, AbbVie Deutschland GmbH and Co KG

Resource Type: commercial organization

Keywords: pharmaceutical, advanced therapy, biopharmaceutical, research, global health, commercial organization

Resource Name: AbbVie

Resource ID: SCR_010484

Alternate IDs: nlx_158067, grid.472726.2

Alternate URLs: <https://ror.org/024e28c54>

Record Creation Time: 20220129T080259+0000

Record Last Update: 20260801T190414+0000

Ratings and Alerts

No rating or validation information has been found for AbbVie.

No alerts have been found for AbbVie.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 914 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Aldoss I, et al. (2025) Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. *Haematologica*, 110(5), 1105.

Simacek CA, et al. (2025) Postnatal development of vasoactive intestinal polypeptide-expressing GABAergic interneurons in mouse somatosensory cortex. *Acta physiologica (Oxford, England)*, 241(2), e14265.

Trachtman H, et al. (2025) Precision Medicine Proof-of-Concept Study of a TNF Inhibitor in FSGS and Treatment-Resistant Minimal Change Disease. *Kidney360*, 6(2), 284.

Lipton RB, et al. (2025) Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials. *Neurology*, 104(2), e210212.

Arias-Badia M, et al. (2025) Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4. *JCI insight*, 10(7).

Jeong YH, et al. (2025) Establishing endotoxin limits to enhance the reliability of in vitro immunogenicity risk assessments. *mAbs*, 17(1), 2458627.

Chen H, et al. (2025) Effects of Paricalcitol on Renal Secondary Hyperparathyroidism and Proteinuria in Dogs With Chronic Kidney Disease. *Journal of veterinary internal medicine*, 39(2), e70063.

Szmirnova I, et al. (2025) Challenges and strategies in dental care for patients with intellectual disabilities in Hungary. *Maxillofacial plastic and reconstructive surgery*, 47(1), 8.

Xiao X, et al. (2025) Deficiency of orexin receptor type 1 in dopaminergic neurons increases novelty-induced locomotion and exploration. *eLife*, 12.

Celine G, et al. (2025) Temporal characterisation and electrophysiological implications of TBI-induced serine/threonine kinase activity in mouse cortex. *Cellular and molecular life sciences : CMLS*, 82(1), 102.

Garg R, et al. (2025) In vitro Stability Study of a Panel of Commercial Antibodies at Physiological pH and Temperature as a Guide to Screen Biologic Candidate Molecules for the Potential Risk of In vivo Asparagine Deamidation and Activity Loss. *Pharmaceutical research*, 42(2), 353.

Wijaya LS, et al. (2025) Spatio-temporal transcriptomic analysis reveals distinct nephrotoxicity, DNA damage, and regeneration response after cisplatin. *Cell biology and toxicology*, 41(1), 49.

Burmester GR, et al. (2025) Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease. *RMD open*, 11(2).

Weidling I, et al. (2025) hiPSC-neurons recapitulate the subtype-specific cell intrinsic nature of susceptibility to neurodegenerative disease-relevant aggregation. *Acta neuropathologica communications*, 13(1), 108.

Krohmer E, et al. (2025) Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin. *Cardiovascular drugs and therapy*, 39(2), 325.

Nam H, et al. (2025) Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First-Line Chemotherapy. *Thoracic cancer*, 16(2), e15522.

Ezzedine K, et al. (2025) Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index. *JAMA dermatology*, 161(1), 39.

Crowley A, et al. (2025) Clinical Validation and Outcome Measures From Bend Ease: A Novel, Sensor-Based Digital Measurement Tool for Assessing At-Home Morning Stiffness and Spinal Range of Motion in Axial Spondyloarthritis. *Rheumatology and therapy*, 12(2), 337.

Agarwal S, et al. (2025) Intermediate Vision Following Monofocal IOL Implantation. *Clinical ophthalmology (Auckland, N.Z.)*, 19, 617.

Li M, et al. (2025) Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine. *Drug design, development and therapy*, 19, 1231.